β-Cyclodextrin and Hyaluronic Acid-Modified Targeted Nanodelivery System for Atherosclerosis Prevention
ACS Applied Materials & Interfaces · 2024
DOI: 10.1021/acsami.4c01540 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2024. Verfasst von Jinjin Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Xi'an Jiaotong University, Xi'an 710000. China. Hauptthemen laut MEDLINE: Hyaluronic Acid, Atherosclerosis, beta-Cyclodextrins, Nanoparticles. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Shaanxi Administration of Traditional Chinese Medicine, Shaanxi Provincial Science and Technology Department.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Xi'an Jiaotong University, Xi'an 710000. China.
ORCID-Profile: Xiaofeng Niu
Förderung
- Shaanxi Administration of Traditional Chinese Medicine
- Shaanxi Provincial Science and Technology Department
Zitieren
APA
Yu, J., Ma, Y., Zhang, X., Wang, S., Zhou, L., Liu, X., Li, L., Liu, L., Song, H., Luo, Y., Wen, S., Li, W., & Niu, X. (2024). β-Cyclodextrin and Hyaluronic Acid-Modified Targeted Nanodelivery System for Atherosclerosis Prevention. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c01540
Vancouver
Yu J, Ma Y, Zhang X, Wang S, Zhou L, Liu X, et al. β-Cyclodextrin and Hyaluronic Acid-Modified Targeted Nanodelivery System for Atherosclerosis Prevention. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c01540
BibTeX
@article{Yu2024,
author = {Yu, Jinjin and Ma, Yajing and Zhang, Xinya and Wang, Siqi and Zhou, Lili and Liu, Xinyao and Li, Lingli and Liu, Lingyi and Song, Huixin and Luo, Yuzhi and Wen, Sha and Li, Weifeng and Niu, Xiaofeng},
title = {β-Cyclodextrin and Hyaluronic Acid-Modified Targeted Nanodelivery System for Atherosclerosis Prevention},
journal = {ACS Applied Materials & Interfaces},
year = {2024},
doi = {10.1021/acsami.4c01540}
}
EUVIMED